{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:11:44Z","timestamp":1790626304705,"version":"4.1.0"},"reference-count":21,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T00:00:00Z","timestamp":1591315200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["Senior Research Fellowship ID1061041"],"award-info":[{"award-number":["Senior Research Fellowship ID1061041"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>With rising use worldwide, pregabalin is increasingly implicated in poisoning deaths. We aimed to investigate the clinical effects and complications of pregabalin poisoning.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This is a retrospective review of patients presenting with pregabalin poisoning to two tertiary toxicology units from 1 July 2014 to 30 June 2019. Patients were identified from prospective databases maintained by both units and data were extracted from these in addition to medical records.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>There were 488 presentations in 413 patients (237 [57%] male) over the five\u2010year period. The median age was 41 years (IQR 31\u201350 years). Deliberate self\u2010poisonings accounted for 342 (70%) presentations, with 121 (25%) recreational exposures. Recreational exposures increased over the period from 2 (4%) in the first year to 54 (39%) presentations in the final year. The median dose of pregabalin was 1200 mg (IQR 600\u20103000 mg, range 75\u201016 800 mg). Co\u2010ingestions occurred in 427 (88%) presentations, with sedating agents being co\u2010ingested in 387 (79%)\u2014most commonly opioids and benzodiazepines in 201 (41%) and 174 (36%) presentations respectively. Coma (GCS &lt; 9) occurred in 89 (18%) cases, with 52 (11%) patients being intubated. Only one (0.2%) of these patients had not co\u2010ingested a sedating agent. Hypotension occurred in 26 (5%) cases, all with co\u2010ingestants. Seizures occurred in 11 (2%) cases, 3\/59 (5%) in pregabalin\u2010only overdoses. The median length of stay was 16.5 hours (IQR 10\u201325 hours).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Pregabalin overdose does not cause severe toxicity, but rather mild sedation and, uncommonly, seizures. Coma is common in the presence of sedating co\u2010ingestants. Recreational use is increasing.<\/jats:p><\/jats:sec>","DOI":"10.1111\/bcp.14348","type":"journal-article","created":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T15:39:17Z","timestamp":1588779557000},"page":"2435-2440","source":"Crossref","is-referenced-by-count":46,"title":["Pregabalin poisoning and rising recreational use: a retrospective observational series"],"prefix":"10.1111","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1176-7923","authenticated-orcid":false,"given":"Katherine Z.","family":"Isoardi","sequence":"first","affiliation":[{"name":"Clinical Toxicology Unit Princess Alexandra Hospital  Brisbane Queensland Australia"},{"name":"Faculty of Medicine University of Queensland  Brisbane Queensland Australia"},{"name":"Clinical Toxicology Research Group University of Newcastle  Newcastle New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Polkinghorne","sequence":"additional","affiliation":[{"name":"Clinical Toxicology Unit Princess Alexandra Hospital  Brisbane Queensland Australia"},{"name":"Faculty of Medicine University of Queensland  Brisbane Queensland Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Harris","sequence":"additional","affiliation":[{"name":"Clinical Toxicology Unit Princess Alexandra Hospital  Brisbane Queensland Australia"},{"name":"Faculty of Medicine University of Queensland  Brisbane Queensland Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1519-7419","authenticated-orcid":false,"given":"Geoffrey K.","family":"Isbister","sequence":"additional","affiliation":[{"name":"Clinical Toxicology Research Group University of Newcastle  Newcastle New South Wales Australia"},{"name":"Department of Clinical Toxicology and Pharmacology, Calvary Mater Newcastle  Newcastle New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,6,5]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2017.08.430"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0700-x"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.13843"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.14412"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0042-101868"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2017.7856"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.5694\/mja14.01116"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-017-0616-y"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.5694\/mja2.12036"},{"key":"e_1_2_11_11_1","unstructured":"Lyrica\u00ae(pregabalin) Product Information leaflet.Sydney: Pfizer Australia. Version pfplyric11019. Revised 11 October 2019. Available at:http:\/\/secure.healthlinks.net.au\/content\/pf\/retriever.cfm?product=pfplyric10113. Accessed 22 October2019."},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2017.01.013"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/15563650801986497"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13181-014-0384-5"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13181-010-0052-3"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2044.2006.04913.x"},{"key":"e_1_2_11_17_1","first-page":"1","article-title":"Use of a tablet\u2010based application for clinical handover and data collection","volume":"11","author":"Downes MA","year":"2019","journal-title":"Clin Toxicol"},{"key":"e_1_2_11_18_1","unstructured":"Pharmaceutical Benefits Scheme (PBS).Expenditure and Prescriptions Twelve Months to 30 June 2018. Canberra: PBS; 201. Available at:https:\/\/www.pbs.gov.au\/statistics\/expenditure-prescriptions\/2017-2018\/expenditure-and-prescriptions-twelve-months-to-30-june-2018.pdf. Accessed 22 October2019."},{"key":"e_1_2_11_19_1","unstructured":"Prescription Cost Analysis. \u2013England 2013 and England 2018. NHS England.https:\/\/digital.nhs.uk\/data-and-information\/publications\/statistical\/prescription-cost-analysis. Accessed 16 March2020."},{"key":"e_1_2_11_20_1","unstructured":"Advice for prescribers on the risk of the misuse of pregabalin and gabapentin. December2014. Public Health England and NHS England.https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/385791\/PHE-NHS_England_pregabalin_and_gabapentin_advice_Dec_2014.pdf. Accessed 16 March 2020."},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2005.02546.x"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2007.03.009"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbcp.14348","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.14348","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcp.14348","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.14348","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T06:11:50Z","timestamp":1693807910000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.14348"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,5]]},"references-count":21,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["10.1111\/bcp.14348"],"URL":"https:\/\/doi.org\/10.1111\/bcp.14348","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,5]]}}}